Loay Kassem, Assistant Professor of clinical oncology at Kasr AlAiny School of Medicine, Cairo University, shared a post on LinkedIn:
“We might think that doing a successful surgery for lung cancer is enough. Unfortunately, this is wrong, even in the rare occasion where lung cancer is diagnosed early.
At 5 years, almost one in every 2 patients who received chemotherapy alone and did a successful surgery died of cancer. The good news is that the addition of only 3 cycles of immunotherapy before surgery could reduce the mortality.
In the CheckMate 816 trial, the addition of 3 cycles of Nivolumab to platinum-based chemotherapy as neoadjuvant therapy significantly improved OS by 10% at 5 years compared with chemotherapy. The 5-year OS rate was 65% with nivolumab plus chemotherapy compared with 55% with chemotherapy alone.
I find that such indication gives a high impact at a relatively low cost. Thanks OncologyME for the nice graphic.”
More posts featuring Loay Kassem.